Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma-Reference-Cited by-同舟云学术

Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma

Published:2020-10-05 Issue:11 Volume:11 Page:3243-3251
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Castañeda‐Zárraga Anahí¹,Rodríguez‐Cid Jerónimo Rafael²^ORCID,Flores‐Mariñelarena Rodrigo Rafael³,Trinidad‐Bibiano Héctor⁴,Martínez‐Herrera José Fabián²,Sánchez‐Ríos Carla Paola²,Fernández‐Garibay Valeria Michelle⁵,Alatorre‐Alexander Jorge Arturo²,Martínez‐Barrera Luis²,Santillán‐Doherty Patricio Javier⁶,Vega‐Memije María Elisa¹

Affiliation:

1. Department of Dermatology Hospital General Dr. Manuel Gea Gónzalez Mexico City Mexico

2. Department of Oncology Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas Mexico City Mexico

3. Department of Internal Medicine Fundación Clínica Médica Sur Mexico City Mexico

4. Department of Pathology Hospital General Dr. Manuel Gea Gónzalez Mexico City Mexico

5. School of Medicine Monterrey Institute of Technology and Higher Education Mexico City Mexico

6. Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas Mexico City Mexico

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13657

Reference35 articles.

1. Cancer statistics, 2018

2. Global Cancer Observatory. Globocan.iarc.fr.http://globocan.iarc.fr/. Published 2020. Accessed 6 January 2020.

3. National consensus of diagnosis and treatment of non‐small cell lung cancer;Arrieta O;Rev Invest Clin,2013

4. Frequency of and variables associated with the EGFR mutation and its subtypes

5. EGFR Antagonists in Cancer Treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer;Technology in Cancer Research & Treatment;2024-01